Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma

Table 1

TKI and mAbs approved by FDA for use of cancer therapy.

Category	Name	Targets	Uses
TKI	Dasatinib	BCR-ABL, SRC family, c-KIT, PDGFR	Chronic myeloid leukemia (CML),; acute lymphocytic leukemia
	Erlotinib	EGFR	Non-small-cell lung cancer (NSCLC),; pancreatic cancer
	Gefitinib	EGFR	NSCLC
	Imatinib	BCR-ABL, c-KIT, PDGFR	Acute lymphocytic leukemia, CML,; gastrointestinal stromal tumor
	Lapatinib	HER2/neu, EGFR	Breast cancer
	Sorafenib	BRAF, VEGFR, EGFR, PDGFR	Renal cell carcinoma (RCC),; hepatocellular carcinoma (HCC)
	Sunitinib	VEGFR, PDGFR, c-KIT, FLT3	RCC, gastrointestinal stromal tumor
	Temsirolimus	mTOR, VEGF	RCC
	Pazopanib	VEGFR-1, VEGFR-2, VEGFR-3,; PDGF-α/β, and c-KIT	RCC
	Nilotinib	BCR-ABL	CML
	Crizotinib	ALK, HGFR	NSCLC
	Vemurafenib	BRAF	Late-stage melanoma
mAb	Alemtuzumab	CD52	Chronic lymphocytic leukemia
	Bevacizumab	VEGF	Colorectal cancer, NSCLC, RCC
	Cetuximab	EFGR	Colorectal cancer, head and neck cancer
	Gemtuzumab ozogamicin	CD33	Relapsed acute myeloid leukemia
	Ibritumomab tiuxetan	CD20	Non-Hodgkin’s lymphoma (NHL); (with yttrium-90 or indium-111)
	Panitumumab	EGFR	Colorectal cancer
	Rituximab	CD20	NHL
	Tositumomab	CD20	NHL (with iodine-131)
	Trastuzumab	HER2/neu	Breast cancer with HER2/neu overexpression
	Ipilimumab	CTLA-4	Late-stage melanoma